Get insight from foundation experts on research, treatment and prevention, plus the very latest news and events.
Switch on your HIV smarts.
Jean-Michel Molina and colleagues reported this month in The Lancet HIV superiority of the integrase inhibitor dolutegravir (Tivicay) when compared to a boosted-protease inhibitor regimen of darunavir (Prezista) plus ritonavir … Read More
A hearing held on March 25, 2015 at a San Francisco City and County Budget and Finance Committee called attention to the insurance company practice of reclassifying HIV medications as … Read More
Attendees of last month’s 2015 Conference on Retroviruses and Opportunistic Infections (CROI) heard good news about nearly 100% cure rates for HIV/HCV coinfected people using new interferon-free hepatitis C treatment. … Read More
Join us for daily news and commentary on HIV/AIDS treatment, prevention and policy.
The foundation's ongoing forum series bringing research and evidence to bear on timely policy and programmatic issues.